Gemcitabine lipid prodrug nanoparticles: switching the lipid moiety and changing the fate in the bloodstream - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue International Journal of Pharmaceutics Année : 2021

Gemcitabine lipid prodrug nanoparticles: switching the lipid moiety and changing the fate in the bloodstream

Catherine Cailleau
Jean-Philippe Michel
Magali Noiray
Patrick Couvreur
Simona Mura

Résumé

A simple approach to achieve a lipoprotein (LP)-mediated drug delivery is to trigger the spontaneous drug insertion into endogenous lipoproteins in the bloodstream, by means of its chemical modification. Nanoparticles (NPs) made of the squalene-gemcitabine (SQGem) conjugate were found to have a high affinity for plasma lipoproteins while free gemcitabine did not, suggesting a key role of the lipid moiety in this event. Whether the drug conjugation to cholesterol, one of the major lipoprotein-transported lipids, could also promote an analogous interaction was a matter of question. NPs made of the cholesterol-gemcitabine conjugate (CholGem) have been herein thoroughly investigated for their blood distribution profile both in vitro and in vivo. Unexpectedly, contrarily to SQGem, no trace of the CholGem prodrug could be found in the lipoprotein fractions, nor was it interacting with albumin. The investigation of isolated NPs and NPs/LPs physical mixtures provided a further insight into the lack of interaction of CholGem NPs with LPs. Although essential for allowing the self-assembly of the prodrug into nanoparticles, the lipid moiety may not be sufficient to elicit interaction of the conjugated drug with plasma lipoproteins but the whole NP physicochemical features must be carefully considered.
Fichier principal
Vignette du fichier
2021-09-30_Main Article_IJP.pdf (1.27 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03375569 , version 1 (12-10-2021)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Eleonore Coppens, Didier Desmaële, Timothée Naret, Sébastien Garcia-Argote, Sophie Feuillastre, et al.. Gemcitabine lipid prodrug nanoparticles: switching the lipid moiety and changing the fate in the bloodstream. International Journal of Pharmaceutics, In press, 609, pp.121076. ⟨10.1016/j.ijpharm.2021.121076⟩. ⟨hal-03375569⟩
138 Consultations
241 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More